Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21904918 | 0.80 | CREBBP (0.39) | POLBMEN1KMT2AMMP2MMP9 | |
| SCHEMBL16652102 | 0.79 | BRD4 (0.47) | POLBMEN1KMT2ARAB9AMMP2 | |
| SCHEMBL24556490 | 0.75 | BRD4 (0.37) | BRD4 | |
| SCHEMBL23963560 | 0.72 | — | — | |
| SCHEMBL3374696 | 0.72 | MAP2K1 (0.45) | MAP2K1MEN1KMT2ARAB9ABRD4 | |
| SCHEMBL23779850 | 0.71 | F11 (0.34) | POLB | |
| SCHEMBL18894248 | 0.69 | ALDH1A1 (0.41) | POLBRAB9A | |
| SCHEMBL16651268 | 0.69 | BRD4 (0.39) | MAP2K1BRD4 | |
| SCHEMBL20366368 | 0.68 | MAP2K1 (0.39) | POLBMAP2K1MEN1KMT2ARAB9A | |
| SCHEMBL24803761 | 0.68 | POLB (0.35) | POLBMAP2K1BRD4BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873474-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Nuvation Bio Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | POLB 586/4885MAP2K1 1407/4885MEN1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.